Pivotal trial evaluated the safety and efficacy of the Hēlo™ Thrombectomy System for the removal of blood clots from the lungs MENLO PARK, Calif., Nov. 3, 2025 /PRNewswire/ -- Dr. Andrew Klein, ENGULF National Co-Principal Investigator at Piedmont Hospital in Atlanta, today presented the positive results of the pivotal cohort of the ENGULF Investigational Device Exemption (IDE) study as a late-breaking clinical trial at the annual VIVA conference in Las Vegas. The data supports the technologica

The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation Results of STORM-PE demonstrating superior efficacy of CAVT with anticoagulation versus anticoagulation alone were also published in Circulation today ALAMEDA, Calif., Nov. 3, 2

Sarepta Therapeutics’ long-awaited confirmatory study of two of its exon-skipping therapies for forms of Duchenne muscular dystrophy failed to meet its primary endpoint, the company announced Monday. Despite the miss, the company plans to ask the FDA for traditional approval of the drugs, called Amondys 45 and Vyondys 53, based on the results from the nine-year study. The company plans to argue that the study, called ESSENCE, showed “encouraging trends” and that the data were confounded by the C

COA Backs State Efforts to Curb PBM Conflicts of Interest and Protect Patient Access to Local, Affordable Cancer Care WASHINGTON, DC, UNITED STATES, November 3, 2025 / EINPresswire.com / -- The Community Oncology Alliance (COA) has filed an amicus curiae brief with the United States Court of Appeals for the Eighth Circuit in support of Arkansas Act 624, the state’s new law banning pharmacy benefit managers (PBMs) from owning or controlling pharmacies. COA’s brief provides firsthand evidence of h

Poster presentations at ASH highlight advances in the understanding and research of Castleman disease, cold agglutinin disease, B-cell lymphoma, and other hematologic conditions BRIDGEWATER, N.J., Nov. 3, 2025 /PRNewswire/ -- Recordati Rare Diseases Inc. today announced the presentation of new data related to its growing portfolio of treatments for rare hematologic disorders at the 67th American Society of Hematology (ASH) Annual Meeting, which takes place December 6-9, 2025, in Orlando, Fla. I

NEW ROCHELLE, N.Y., Nov. 3, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Shlomo Shinnar, MD, Ph.D. is acknowledged as a Pinnacle Lifetime Member for his contributions to Epilepsy Treatment and Education. Dr. Shlomo Shinnar, an esteemed figure in the fields of medicine and education, continues to revolutionize epilepsy treatment and research while nurturing the next generation of medical professionals. Continue Reading Shlomo Shinnar, MD, Ph.D. With a profound dedication to adv

OnsiteGene details the XDive™ system, an ultra-fast PCR platform capable of completing 40-cycle real-time PCR in under 5 minutes. LOS ALTOS, CA, UNITED STATES, November 3, 2025 / EINPresswire.com / -- OnsiteGene Inc. has published a comprehensive review of its XDive™ Ultra-Fast Real-Time PCR Instrument, examining the system’s architecture, capabilities, certifications, and potential applications across clinical, public health, environmental, agricultural, and veterinary domains. Introduction Ons

LYON, France--(BUSINESS WIRE)--Regulatory News: The ARES study demonstrated a clinically meaningful and durable benefit in patients with gastrointestinal aGvHD, further validating our approach and its potential to redefine the standard of care in this high unmet need MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune m

BOSTON and NEW YORK, Nov. 3, 2025 /PRNewswire/ -- Harbor IT, a national provider of cybersecurity and IT services, has acquired New England Network Solutions (NENS), a Greater Boston-based managed service provider known for its operational maturity and advanced expertise in healthcare and life sciences. Harbor IT began in cybersecurity with a mission to bridge the gap between cybersecurity and IT operations. Today it delivers a security-led managed services platform for regulated and complex env

American Heart Association consortium advances development of evidence-based health tech solutions Being part of this network of innovators allows us to collaborate with organizations that share our vision for advancing healthcare through responsible, science-driven AI” — Navid Alipour CEO of CureMetrix, Inc SAN DIEGO, CA, UNITED STATES, November 3, 2025 / EINPresswire.com / -- CureMetrix joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation American H